Letters sent to healthcare professionals in June 2017

Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).

In June 2017, the following letters were sent to relevant healthcare professionals:

Article citation: Drug Safety Update volume 10 issue 12, July 2017: 4.

Published 20 July 2017